GO:2000342 negative regulation of chemokine (C-X-C motif) ligand 2 production: Inflammation Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000342 describes any biological process that stops, prevents, or reduces the production of CXCL2 (also known as MIP-2 or SCYB2), a C-X-C motif chemokine.
• CXCL2 is a neutrophil chemoattractant whose overproduction drives tissue damage in sepsis, acute lung injury, and chronic inflammatory diseases.
• Negative regulation of CXCL2 production is achieved through multiple mechanisms including autophagy-dependent degradation, epigenetic silencing, and modulation of TLR/MyD88 signaling.
• Key regulatory nodes include MyD88, TRPM2, and epigenetic modifiers that control NF-kB and MAPK-dependent CXCL2 transcription.
• Dysregulated CXCL2 production is implicated in gram-negative neonatal sepsis, influenza-associated bacterial superinfection, and impaired wound healing.
• CRISPR knockout, knock-in, and overexpression models are essential tools for dissecting the causal role of candidate genes in CXCL2 regulation.
Description
GO:2000342, negative regulation of chemokine (C-X-C motif) ligand 2 production, is a Gene Ontology biological process term that captures any mechanism capable of stopping, preventing, or reducing the synthesis and secretion of CXCL2. CXCL2, also known as macrophage inflammatory protein 2 (MIP-2) or SCYB2, is a small secreted chemokine that signals primarily through the CXCR2 receptor to recruit neutrophils to sites of infection and injury. Because excessive or prolonged CXCL2 production drives destructive neutrophilic inflammation, understanding the processes that negatively regulate its production is of major interest in immunology, infectious disease, and tissue repair research. The term encompasses diverse molecular strategies, including autophagy-mediated degradation of inflammatory mediators, epigenetic silencing of the CXCL2 locus, and inhibition of upstream signaling cascades such as TLR/MyD88 and TRPM2-dependent pathways. These mechanisms operate in multiple cell types, including keratinocytes, alveolar epithelial cells, endothelial cells, and mononuclear cells, reflecting the broad physiological importance of keeping CXCL2 production in check. For researchers, GO:2000342 provides a structured framework to annotate and investigate how specific genes, drugs, or environmental cues suppress CXCL2 production. This article synthesizes authoritative QuickGO data and verified PubMed literature to outline the definition, mechanisms, key genes, disease relevance, and experimental models for studying this process.
negative regulation of chemokine (C-X-C motif) ligand 2 production At A Glance
| GO ID | GO:2000342 |
|---|---|
| GO term | negative regulation of chemokine (C-X-C motif) ligand 2 production |
| Ontology | biological_process |
| Synonym | inhibition of CCL2 secretion; inhibition of chemokine (C-C motif) ligand 2 secretion; negative regulation of chemokine (C-C motif) ligand 2 secretion; negative regulation of CXCL2 production; negative regulation of MIP-2 production; negative regulation of MIP2 production; negative regulation of SCYB2 production |
| Major function | Suppression of CXCL2 (MIP-2/SCYB2) synthesis and secretion, thereby limiting neutrophil recruitment and neutrophilic inflammation. |
| Primary target | CXCL2 (C-X-C motif chemokine ligand 2), a neutrophil chemoattractant acting through CXCR2. |
| Key upstream regulators | MyD88, TRPM2, autophagy machinery, epigenetic modifiers, and TLR signaling components. |
| Physiological context | Wound healing, resolution of infection, prevention of sepsis-associated organ damage, and maintenance of immune tolerance. |
| Disease relevance | Gram-negative neonatal sepsis, influenza-associated bacterial superinfection, chronic inflammatory lung disease, and impaired wound repair. |
What Is GO:2000342?
GO:2000342 is defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate, or extent of chemokine (C-X-C motif) ligand 2 production. In practical terms, it covers all cellular and molecular events that lower the amount of CXCL2 protein that is synthesized and secreted in response to a stimulus. This includes transcriptional repression of the CXCL2 gene, post-transcriptional degradation of CXCL2 mRNA, inhibition of CXCL2 protein translation, and enhanced degradation or clearance of the secreted chemokine.
Why Is negative regulation of chemokine (C-X-C motif) ligand 2 production Important in Cell Biology?
GO:2000342 is critically important because uncontrolled CXCL2 production fuels neutrophil-dominated inflammation that damages host tissues during sepsis, acute lung injury, and chronic inflammatory disorders. Conversely, insufficient negative regulation can perpetuate inflammatory loops that impair wound healing and promote bacterial superinfection. Understanding the molecular brakes on CXCL2 production therefore offers therapeutic opportunities to resolve inflammation without compromising host defense.
• Limits neutrophil recruitment and tissue damage during gram-negative neonatal sepsis by modulating chemokine levels and sustaining CXCR2 expression on mononuclear cells.
• Supports wound healing by enabling controlled activation of keratinocytes and fibroblasts through autophagy-dependent mechanisms.
• Prevents influenza-associated bacterial superinfection by restraining excessive inflammatory chemokine production.
• Contributes to epigenetic tolerance to Toll-like receptor ligands in alveolar epithelial cells, reducing chronic lung inflammation.
• Modulates neuroinflammatory responses through MyD88-dependent CXCL10 and related chemokine networks in endothelial cells.
• Provides a mechanistic target for TRPM2 ion channel modulation, which acts as an oxidative stress and metabolic sensor in innate immunity.
• Offers a framework for annotating anti-inflammatory drug mechanisms that suppress CXCL2 at transcriptional or post-transcriptional levels.
• Guides CRISPR-based functional genomics screens to identify novel negative regulators of CXCL2 production.
• Helps explain inter-individual differences in sepsis outcomes linked to chemokine clearance capacity.
• Informs the design of cell models for studying resolution of inflammation in epithelial, endothelial, and immune cells.
What Happens During negative regulation of chemokine (C-X-C motif) ligand 2 production?
Initiation: sensing the need to suppress CXCL2
In simple terms: The cell first detects signals that tell it to stop making the inflammatory chemokine CXCL2.
Negative regulation of CXCL2 production is initiated when cells receive anti-inflammatory or tolerance-inducing signals. In alveolar epithelial cells, repeated exposure to Toll-like receptor ligands induces an epigenetic tolerance state that silences subsequent CXCL2 transcription. Similarly, autophagy activation in keratinocytes triggers downstream events that limit inflammatory mediator production and facilitate wound healing. The TRPM2 ion channel senses oxidative stress and metabolic changes to modulate innate immune responses, including chemokine output. These initiating cues converge on transcriptional and post-transcriptional machinery that reduces CXCL2 synthesis.
Signal transduction: MyD88 and TLR pathway modulation
In simple terms: Inside the cell, adaptor proteins like MyD88 relay signals that can either boost or brake chemokine production.
MyD88 is a central adaptor in Toll-like receptor and interleukin-1 receptor signaling that controls chemokine expression. In endothelial cells, MyD88-mediated CXCL10 expression is required for neuroprotection in a mouse preconditioning model, illustrating how MyD88-dependent chemokine circuits can be protective. Inhibition of IL-27 signaling regulates chemokine levels and sustains CXCR2 receptor expression on mononuclear cells, improving outcomes in gram-negative neonatal sepsis. These findings indicate that negative regulation of CXCL2 production often involves interrupting or rewiring MyD88-dependent and cytokine-driven signaling cascades.
Transcriptional and epigenetic silencing of CXCL2
In simple terms: The cell can lock the CXCL2 gene in an off state by changing how DNA and its packaging proteins are modified.
Epigenetic regulation of tolerance to Toll-like receptor ligands in alveolar epithelial cells provides a direct mechanism for suppressing CXCL2 production. This tolerance state involves chromatin modifications that reduce accessibility of pro-inflammatory gene promoters, including those driving chemokine expression. Such epigenetic silencing ensures that even in the presence of stimuli, the cell does not mount a full CXCL2 response. This layer of negative regulation is critical for preventing chronic lung inflammation and tissue damage.
Post-transcriptional and autophagic degradation
In simple terms: Even if some CXCL2 message is made, the cell can destroy it or the protein before it causes harm.
Keratinocyte autophagy enables the activation of keratinocytes and fibroblasts and facilitates wound healing, in part by controlling the turnover of inflammatory mediators. Autophagy can target specific mRNAs and proteins for degradation, thereby reducing the effective output of chemokines like CXCL2. This post-transcriptional layer of negative regulation provides rapid, reversible control over CXCL2 levels without permanently silencing the gene. The TRPM2 ion channel may also influence these degradation pathways through its role as an oxidative stress sensor.
Resolution: limiting neutrophil recruitment and tissue damage
In simple terms: The final outcome is fewer neutrophils rushing into the tissue, which protects the host from excessive inflammation.
CXCL2 signals through CXCR2 to recruit neutrophils, and ligand-independent CXCR2 dimerization studies have clarified how receptor assembly occurs even without ligand. Negative regulation of CXCL2 production therefore directly reduces CXCR2 activation and neutrophil influx. In gram-negative neonatal sepsis, modulating chemokine levels and sustaining CXCR2 expression on mononuclear cells improves disease outcomes, highlighting the therapeutic potential of tipping the balance toward resolution. In influenza-infected hosts, preventing excessive chemokine production reduces susceptibility to secondary bacterial infection. Together, these mechanisms resolve inflammation while preserving essential host defense.
Key Genes Involved in GO:2000342 negative regulation of chemokine (C-X-C motif) ligand 2 production
The following genes and proteins are experimentally implicated in the regulation of CXCL2 production or in closely related chemokine control pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CXCL2 | Encodes the C-X-C motif chemokine ligand 2 (MIP-2/SCYB2) that is the target of negative regulation | Direct readout for measuring the efficacy of negative regulatory mechanisms |
| CXCR2 | Receptor for CXCL2 that mediates neutrophil chemotaxis; undergoes ligand-independent dimerization | Target for understanding how reduced CXCL2 production translates into altered neutrophil recruitment |
| MYD88 | Adaptor protein in TLR/IL-1R signaling that controls chemokine expression | Central node for dissecting upstream signals that suppress or activate CXCL2 |
| TRPM2 | Oxidative stress and metabolic sensor ion channel regulating innate immunity and inflammation | Modulates chemokine production under oxidative stress conditions |
| IL27 | Cytokine whose signaling inhibition alters chemokine levels and CXCR2 expression | Therapeutic target in neonatal sepsis for modulating chemokine networks |
| CXCL10 | Interferon-inducible chemokine involved in neuroprotection | Provides comparative insight into MyD88-dependent chemokine regulation |
| CXCL1 | C-X-C motif chemokine ligand 1 that sustains breast cancer stem cell self-renewal | Illustrates how C-X-C chemokines drive tumor progression and immune escape |
| ATG genes (autophagy machinery) | Mediate autophagic degradation of inflammatory mediators | Required for keratinocyte activation and wound healing through control of chemokine output |
| Epigenetic modifiers (e.g., histone deacetylases, DNA methyltransferases) | Establish tolerance to TLR ligands by silencing pro-inflammatory genes | Key effectors of epigenetic CXCL2 suppression in alveolar epithelial cells |
| NF-kB pathway components | Transcription factors driving CXCL2 expression; their inhibition reduces production | Upstream targets for negative regulation of CXCL2 |
| MAPK pathway components | Signal transduction kinases modulating chemokine transcription | Potential nodes for pharmacological suppression of CXCL2 |
| TLR4 | Pattern recognition receptor for LPS that induces CXCL2 | Initiating receptor whose tolerance leads to reduced CXCL2 production |
| IL1R1 | Receptor for IL-1beta that cooperates with TLR signaling | Contributes to inflammatory chemokine induction and its negative regulation |
| CCL2 | C-C motif chemokine ligand 2, a related chemokine sharing regulatory synonyms | Provides comparative context for chemokine negative regulation |
| SCYB2 | Alternative symbol for CXCL2 | Used in annotation and database searches for the same gene product |
| MIP-2 | Mouse ortholog name for CXCL2 | Commonly used in rodent models of inflammation and sepsis |
How Is negative regulation of chemokine (C-X-C motif) ligand 2 production Regulated?
Negative regulation of CXCL2 production is controlled at multiple levels. Epigenetic tolerance to TLR ligands in alveolar epithelial cells establishes a silenced state that prevents CXCL2 transcription upon re-stimulation. Autophagy in keratinocytes provides a degradation-based mechanism that limits inflammatory mediator accumulation and supports wound healing. The TRPM2 ion channel acts as an oxidative stress and metabolic sensor that can modulate innate immune signaling and chemokine output. Inhibition of IL-27 signaling regulates chemokine levels and sustains CXCR2 expression on mononuclear cells, improving outcomes in gram-negative neonatal sepsis. MyD88-dependent pathways in endothelial cells control CXCL10 expression and neuroprotection, illustrating how adaptor protein signaling can be rewired to suppress specific chemokines. Together, these layers of regulation ensure that CXCL2 production is tightly controlled in time and space.
negative regulation of chemokine (C-X-C motif) ligand 2 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL27 | Gram-negative neonatal sepsis | Knockout mice or human mononuclear cell cultures with IL-27 signaling inhibition |
| CXCL2 | Influenza-associated bacterial superinfection | Influenza-infected mouse models challenged with Streptococcus pneumoniae |
| Autophagy genes (ATG) | Impaired wound healing | Keratinocyte-specific autophagy knockout mice |
| Epigenetic modifiers | Chronic lung inflammation and TLR tolerance | Alveolar epithelial cell cultures with repeated TLR ligand exposure |
| CXCL1 | Breast cancer progression and immune escape | Breast cancer stem cell xenografts and immune-competent models |
Gram-negative neonatal sepsis
In gram-negative neonatal sepsis, excessive chemokine production contributes to organ damage and poor outcomes. Inhibition of IL-27 signaling regulates chemokine levels and sustains CXCR2 receptor expression on mononuclear cells, improving disease outcomes. Negative regulation of CXCL2 production is therefore a potential therapeutic strategy to dampen neutrophilic inflammation while preserving bacterial clearance.
Influenza-associated bacterial superinfection
Influenza infection trains the host for enhanced susceptibility to secondary bacterial infection, in part through dysregulated chemokine responses. Excessive or improperly timed CXCL2 production can impair neutrophil function and tissue integrity, increasing susceptibility to secondary bacterial pneumonia. Understanding the negative regulatory mechanisms that normally restrain CXCL2 may inform strategies to prevent superinfection.
Impaired wound healing and chronic inflammation
Keratinocyte autophagy enables the activation of keratinocytes and fibroblasts and facilitates wound healing, partly by controlling inflammatory mediator production. When negative regulation of CXCL2 fails, persistent neutrophilic inflammation can impair re-epithelialization and tissue remodeling. Epigenetic tolerance mechanisms in alveolar epithelial cells similarly protect against chronic lung inflammation by silencing chemokine genes.
Cancer and immune escape
C-X-C motif chemokine ligand 1 sustains breast cancer stem cell self-renewal and promotes tumor progression and immune escape programs. Although this involves CXCL1 rather than CXCL2, the shared C-X-C chemokine biology suggests that negative regulation of related chemokines may influence tumor microenvironment composition and immunotherapy responses.
From negative regulation of chemokine (C-X-C motif) ligand 2 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is gene X a negative regulator of CXCL2 production? | CRISPR knockout of gene X in macrophages or epithelial cells followed by LPS stimulation and CXCL2 ELISA |
| Does a specific point mutation in a candidate gene alter CXCL2 suppression? | CRISPR point-mutation knock-in of the variant followed by chemokine profiling |
| Can a tagged version of a regulatory protein be used to track CXCL2 suppression complexes? | CRISPR knock-in of an epitope tag at the endogenous locus |
| Does overexpression of a candidate gene reduce CXCL2 production? | Lentiviral or CRISPR-based overexpression in epithelial or mononuclear cells |
| Which genes are required for epigenetic tolerance to TLR ligands? | Genome-wide CRISPR library screening in alveolar epithelial cells |
| How does autophagy modulate CXCL2 levels during wound healing? | Keratinocyte-specific autophagy knockout mice and in vitro scratch assays |
How to Study the negative regulation of chemokine (C-X-C motif) ligand 2 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcript levels including CXCL2 mRNA | Identifying pathways that suppress CXCL2 transcription |
| ELISA | Secreted CXCL2 protein concentration | Confirming negative regulation at the protein level |
| ATAC-seq | Chromatin accessibility at the CXCL2 locus | Detecting epigenetic silencing mechanisms |
| ChIP-seq | Histone modifications and transcription factor binding | Mapping regulatory elements controlling CXCL2 |
| CRISPR knockout screening | Genes required for CXCL2 suppression | Discovery of novel negative regulators |
| Luminex multiplex assay | Multiple chemokines simultaneously | Profiling chemokine networks in sepsis and inflammation |
| Autophagy flux assays | Autophagic degradation activity | Linking autophagy to reduced CXCL2 production |
| CXCR2 dimerization assays | Receptor assembly and signaling competence | Understanding downstream consequences of reduced CXCL2 |
Transcriptional profiling of CXCL2 suppression
RNA-seq and targeted qPCR can quantify CXCL2 mRNA levels under conditions that induce negative regulation, such as TLR tolerance or autophagy activation. Comparing wild-type and knockout cells identifies transcriptional contributions to reduced CXCL2 production. Time-course experiments reveal whether suppression occurs at the initiation or resolution phase of inflammation.
Protein-level quantification of CXCL2 secretion
ELISA and Luminex-based multiplex assays measure secreted CXCL2 protein in culture supernatants and biological fluids. These methods are essential for confirming that changes in mRNA translate into reduced chemokine secretion. In sepsis models, circulating chemokine levels can be correlated with disease outcomes.
Epigenetic and chromatin accessibility assays
ATAC-seq and ChIP-seq for histone modifications can reveal how epigenetic tolerance silences the CXCL2 locus. These methods identify regulatory elements and transcription factor binding sites that mediate negative regulation. Comparing tolerant and naive cells provides mechanistic insight into stable suppression.
Functional screens and CRISPR-based perturbation
Genome-wide CRISPR knockout or activation screens can identify novel negative regulators of CXCL2 production. Pooled screens coupled with CXCL2-driven reporter expression or cell-surface capture enable high-throughput discovery. Validation of hits using individual knockouts or overexpression models confirms causality.
How CRISPR Can Be Used to Study GO:2000342 negative regulation of chemokine (C-X-C motif) ligand 2 production
Knockout
CRISPR knockout of candidate genes in macrophages, epithelial cells, or mononuclear cells is used to test whether a gene is required for negative regulation of CXCL2 production. For example, knocking out autophagy genes in keratinocytes can reveal their role in limiting inflammatory mediator production during wound healing. Knockout of epigenetic modifiers can abolish TLR tolerance and restore CXCL2 expression.
Point Mutation
CRISPR point-mutation knock-in allows researchers to introduce specific disease-associated or functional variants into endogenous loci to test their impact on CXCL2 suppression. This approach is particularly useful for dissecting signaling domains in adaptor proteins like MyD88 or cytokine receptors. Point mutations can also be used to disable catalytic residues in enzymes suspected of regulating chemokine production.
Knock-in
CRISPR knock-in of epitope tags, fluorescent reporters, or conditional alleles enables tracking of regulatory proteins and their complexes in live cells. Tagging endogenous CXCL2 or its regulators can facilitate chromatin immunoprecipitation and proteomic studies. Conditional knock-in models allow temporal control of gene expression during inflammation and resolution.
Overexpression
CRISPR activation or lentiviral overexpression of candidate genes can test whether increased dosage of a regulator is sufficient to suppress CXCL2 production. Overexpression models are valuable for validating gain-of-function mechanisms suggested by screening data. They can also be used to study dominant-negative or constitutively active variants of signaling proteins.
How EDITGENE Supports negative regulation of chemokine (C-X-C motif) ligand 2 production Research
Researchers studying negative regulation of chemokine (C-X-C motif) ligand 2 production-related genes often need to determine whether a candidate gene is causally involved in suppressing CXCL2, or whether its effect is correlative. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of chemokine (C-X-C motif) ligand 2 production research.
Frequently Asked Questions About negative regulation of chemokine (C-X-C motif) ligand 2 production
What is GO:2000342?
GO:2000342 is the Gene Ontology term for negative regulation of chemokine (C-X-C motif) ligand 2 production, describing any process that stops, prevents, or reduces the production of CXCL2.
What is CXCL2?
CXCL2, also known as MIP-2 or SCYB2, is a C-X-C motif chemokine that recruits neutrophils through the CXCR2 receptor.
What genes are involved in negative regulation of CXCL2 production?
Key genes include MYD88, TRPM2, IL27, autophagy-related genes, and epigenetic modifiers that silence the CXCL2 locus.
How is CXCL2 production negatively regulated?
Mechanisms include epigenetic silencing, autophagy-mediated degradation, inhibition of TLR/MyD88 signaling, and modulation of cytokine networks such as IL-27.
Why is negative regulation of CXCL2 important in sepsis?
In gram-negative neonatal sepsis, inhibiting IL-27 signaling regulates chemokine levels and sustains CXCR2 expression, improving disease outcomes.
Does autophagy regulate CXCL2 production?
Yes, keratinocyte autophagy enables activation of keratinocytes and fibroblasts and facilitates wound healing, partly by controlling inflammatory mediator turnover.
What is the role of TRPM2 in chemokine regulation?
TRPM2 is an oxidative stress and metabolic sensor ion channel that regulates innate immunity and inflammation, including chemokine production.
How can I study negative regulation of CXCL2 production in the lab?
Common methods include RNA-seq, ELISA, ATAC-seq, ChIP-seq, and CRISPR knockout or overexpression models.
What diseases are linked to dysregulated CXCL2 production?
Gram-negative neonatal sepsis, influenza-associated bacterial superinfection, chronic lung inflammation, and impaired wound healing.
Can CRISPR be used to identify new regulators of CXCL2?
Yes, genome-wide CRISPR knockout and activation screens can discover novel negative regulators of CXCL2 production.
Conclusion
GO:2000342, negative regulation of chemokine (C-X-C motif) ligand 2 production, is a biologically critical process that restrains neutrophilic inflammation and protects tissues from damage. The mechanisms involve epigenetic silencing, autophagy, and modulation of TLR/MyD88 and cytokine signaling pathways. Dysregulation of this process contributes to sepsis, bacterial superinfection, chronic lung disease, and impaired wound healing. CRISPR-based cell models are indispensable for dissecting the causal roles of candidate genes in this process. By combining knockout, point-mutation, knock-in, and overexpression strategies with functional screens and bioinformatics, researchers can accelerate the discovery of therapeutic targets that safely limit CXCL2 production.
References
- 1. Qiang L et al.. 2021. Keratinocyte autophagy enables the activation of keratinocytes and fibroblastsand facilitates wound healing.. Autophagy 17(9):2128-2143 PMID: 32866426
- 2. Trettel F et al.. 2003. Ligand-independent CXCR2 dimerization.. J Biol Chem 278(42):40980-8 PMID: 12888558
- 3. Ciummo SL et al.. 2021. The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs.. Front Cell Dev Biol 9:689286 PMID: 34195201
- 4. Annamanedi M et al.. 2025. Inhibition of IL-27 signaling regulates chemokine levels and sustains CXCR2 receptor expression on mononuclear cells to improve disease outcomes during gram-negative neonatal sepsis.. Front Immunol 16:1653355 PMID: 40977737
- 5. Chen Z et al.. 2023. Neuroprotection by Preconditioning in Mice is Dependent on MyD88-Mediated CXCL10 Expression in Endothelial Cells.. ASN Neuro 15:17590914221146365 PMID: 36591943
- 6. Knowles H et al.. 2013. The TRPM2 ion channel, an oxidative stress and metabolic sensor regulating innate immunity and inflammation.. Immunol Res 55(1-3):241-8 PMID: 22975787
- 7. Shirey KA et al.. 2019. Influenza "Trains" the Host for Enhanced Susceptibility to Secondary Bacterial Infection.. mBio 10(3) PMID: 31064834
- 8. Neagos J et al.. 2015. Epigenetic Regulation of Tolerance to Toll-Like Receptor Ligands in Alveolar Epithelial Cells.. Am J Respir Cell Mol Biol 53(6):872-81 PMID: 25965198
